An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma

U-H Mellqvist; C Paba-Prada; A Palumbo; Torben Plesner; P Sonneveld; P Voorhees; C Byrne; J Harmenberg; E Nordström; P. Richardson

An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma

U-H Mellqvist, C Paba-Prada, A Palumbo, Torben Plesner, P Sonneveld, P Voorhees, C Byrne, J Harmenberg, E Nordström, P. Richardson

Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

Originalsprog	Engelsk
Publikationsdato	2014
Status	Udgivet - 2014
Begivenhed	Annual Congress of the European Hematology Association - Milano, Italien Varighed: 12. jun. 2014 → 15. jun. 2014 Konferencens nummer: 19

Konference

Konference	Annual Congress of the European Hematology Association
Nummer	19
Land/Område	Italien
By	Milano
Periode	12/06/2014 → 15/06/2014

Citationsformater

Mellqvist, U.-H., Paba-Prada, C., Palumbo, A., Plesner, T., Sonneveld, P., Voorhees, P., Byrne, C., Harmenberg, J., Nordström, E., & Richardson, P. (2014). An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma. Abstract fra Annual Congress of the European Hematology Association, Milano, Italien.

@conference{4803f04faec84050bfad876e39414214,

title = "An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma",

author = "U-H Mellqvist and C Paba-Prada and A Palumbo and Torben Plesner and P Sonneveld and P Voorhees and C Byrne and J Harmenberg and E Nordstr{\"o}m and P. Richardson",

year = "2014",

language = "English",

note = "Annual Congress of the European Hematology Association ; Conference date: 12-06-2014 Through 15-06-2014",

}

Mellqvist, U-H, Paba-Prada, C, Palumbo, A, Plesner, T, Sonneveld, P, Voorhees, P, Byrne, C, Harmenberg, J, Nordström, E & Richardson, P 2014, 'An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma', Annual Congress of the European Hematology Association, Milano, Italien, 12/06/2014 - 15/06/2014.

An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma. / Mellqvist, U-H; Paba-Prada, C; Palumbo, A et al.
2014. Abstract fra Annual Congress of the European Hematology Association, Milano, Italien.

Publikation: Konferencebidrag uden forlag/tidsskrift › Konferenceabstrakt til konference › Forskning › peer review

TY - ABST

T1 - An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma

AU - Mellqvist, U-H

AU - Paba-Prada, C

AU - Palumbo, A

AU - Plesner, Torben

AU - Sonneveld, P

AU - Voorhees, P

AU - Byrne, C

AU - Harmenberg, J

AU - Nordström, E

AU - Richardson, P.

N1 - Conference code: 19

PY - 2014

Y1 - 2014

M3 - Conference abstract for conference

T2 - Annual Congress of the European Hematology Association

Y2 - 12 June 2014 through 15 June 2014

ER -

Mellqvist UH, Paba-Prada C, Palumbo A, Plesner T, Sonneveld P, Voorhees P et al.. An ongoing open-label phase 1/2a study of the safety and efficacy of melphalan-flufenamide (melflufen) and dexamethasone combination for patients with relapsed and relapsed-refractory multiple myeloma. 2014. Abstract fra Annual Congress of the European Hematology Association, Milano, Italien.